Objective To evaluate the effects of carvedilol on the cardiac function and serum leptin lever in the treatment of diabetic cardiomyopathy.Methods 40 patients with diabetic cardiomyopathy were randomly divided into carvedilol group and control group.Two groups were given normal therapy and the carvedilol group added carvedilol.The serum levels of leptin and insulin and the heart ultrasound check were measured before and after six months of therapy.Results After therapy the serum levels of leptin and insulin resistance index [ ( 7.18 ± 2.06 ) μg/L,(2.92 ± 0.62) ] were blower than that before therapy in carvedilol group but not control group.After therapy the value of LVEF and E/A were higher[ (46.9 ± 6.8) ％,( 1.05 ± 0.07) ] and LVMI and LVEDd were lower[ ( 108 ± 6 ) g/ m2,(51.8 ± 5.7)mm ] than that before therapy in carvedilol group but not control group( all P ＜ 0.05 ).Conclusion Carvedilol could decrease the levels of serum leptin in patient with diabetic cardiomyopathy and improve insulin resistance and left entricular function.

Antihypertensive Agents ; therapeutic use ; Humans ; Vaccines

Adult ; Humans ; Lead Poisoning, Nervous System ; etiology ; Male

Cardiovascular Diseases ; drug therapy ; Humans ; Renin ; antagonists & inhibitors

Angiotensin-Converting Enzyme Inhibitors ; therapeutic use ; Follow-Up Studies ; Heart Failure ; drug therapy ; Humans ; Retrospective Studies

Blood Pressure ; Humans

Cardiovascular Agents ; therapeutic use ; Chronic Disease ; Clinical Trials as Topic ; Coronary Disease ; drug therapy ; Double-Blind Method ; Humans

Antihypertensive Agents ; therapeutic use ; Drug Therapy, Combination ; Humans ; Hypertension ; drug therapy

Humans ; Hypertension ; therapy

Objective To explore the relation between serum nesfatin-1 ,tumor necrosis factor (TNF)-αand insulin resistance. Methods A total of 105 subjects were enrolled in this study and divided into two groups:patients with newly diagnosed type 2 diabetes mellitus (T2DM group,n= 64)and normal controls (NC group,n= 41). The fasting serum nesfatin-1 and TNF-αlevels were measured by enzyme-linked immuno sorbent assay (ELISA). FPG,HbA1 c,TG,TC,and FIns were also tested. BMI, HOMA-IR,HOMA-β,and ISI were calculated. Results Serum nesfatin-1 and TNF-αlevels were significantly higher in T2DM group than in NC group. Multiple linear regression analysis showed that the most significant influencing factors for nesfatin-1 were TNF-αand ISI(β= 0. 005、-6. 847,P<0. 05). The most significant influencing factors for TNF-αwas HbA1 c (β= 26. 652,P<0. 01). Conclusion Serum nesfatin-1 and TNF-αare significantly elevated in patients with newly diagnosed T2DM,which may influence the glucolipid metabolism through the signal pathway of insulin and play a role in the pathogenesis of T2DM and IR.